A Study to Compare the Pharmacokinetics, Pharmacodynamic, Immunogenicity, and Safety of CKD-706 With US-Dupixent®, and EU-Dupixent® in Healthy Adult Participants.

This study is looking for healthy adults between the ages of 18 and 55. To make sure the study results are clear and consistent, there are some specific health and lifestyle requirements. For example, your body weight and height (Body Mass Index) need to be within a certain range.

Because this is a very careful study, you can't have any major ongoing health problems or a history of serious illnesses. This includes conditions affecting your heart, liver, kidneys, or immune system. You also wouldn't be able to join if you've already taken Dupixent or similar medicines before.

For women, you cannot be pregnant, breastfeeding, or planning to become pregnant during the study. If you are a woman who could become pregnant, special birth control methods will be needed. For men, if your partner could become pregnant, you would also need to use two forms of birth control for several months during and after the study.

If you decide to take part, you'll first have a screening visit to check if you meet all the requirements. If you do, you'll be admitted to a special clinical unit on Day -1 (the day before dosing). On Day 1, you'll receive a single dose of either CKD-706, US-Dupixent, or EU-Dupixent. You won't know which one you're getting because the study is 'double-blind' – meaning neither you nor the researchers will know.

After receiving the medicine, you'll have regular blood tests for a long period, from Day 1 up to Day 85. These blood tests are crucial for understanding how the medicine moves through your body, what effects it has, and if your immune system reacts to it. You'll need to be available for the full study duration, which involves these regular follow-up visits and blood samples. The total duration of your participation will be from the initial screening until the final follow-up visit on Day 85.